US4302368A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nonthrombogenic articles and method of preparation
Assignee: Becton Dickinson and Co
•
Filing: 1979-09-17
•
Granted: 1981-11-24
•
Expires: 1999-09-17
Abstract
Abstract The disclosure is of articles having reduced thrombogenicity and which are useful for purposes requiring their contact with whole blood. The articles comprise solid, polymeric resin substrates to which there is fixed a compound of the formula: ##STR1## wherein R is alkyl of 12 to 18 carbon atoms, inclusive, R 1 is lower alkyl and A is the negative ion of a soluble salt of heparin. The articles advantageously exhibit low toxicity and excellent blood compatibility when used for purposes which bring them into contact with whole blood for prolonged periods of time.
Inventors
- 👤 Betty J. Dudley, deceased
- 👤 Joel L. Williams
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 21:07
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61B; A61B17/00; A61B17/34; A61B17/3415; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0017; C; C08; C08L; C08L5/00; C08L5/10; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/921
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
54 words
An article for use in association with whole blood, which comprises; a solid, polymeric resin substrate; and a compound of the formula: ##STR5## wherein R is alkyl of 12 to 18 carbon atoms, inclusive, R 1 is lower alkyl and A represents the negative ion of a salt of heparin, affixed to said substrate.
Claim 2
Dependent Claim
54 words
An article for use in association with whole blood, which comprises; a solid, polymeric resin substrate; and a compound of the formula: ##STR5## wherein R is alkyl of 12 to 18 carbon atoms, inclusive, R 1 is lower alkyl and A represents the negative ion of a salt of heparin, affixed to said substrate.
Claim 3
Dependent Claim
10 words
The article of claim 1 wherein said resin comprises polyethylene.
Claim 4
Dependent Claim
10 words
The article of claim 1 wherein said resin is polyurethane.
Claim 5
Dependent Claim
10 words
The article of claim 1 wherein said resin is polytetrafluoroethylene.
Claim 6
Dependent Claim
24 words
The article of claim 1 wherein the proportion of heparin affixed to the substrate is at least 2.0 μg/cm 2 of resin substrate surface.
Claim 7
Dependent Claim
37 words
The article of claim 1 wherein the resin is selected from the group consisting of polyethylene, polyacrylics, polypropylene, polyvinyl chloride, polyamides, polyurethanes, polyvinylpyrrolidone, polyvinyl alcohols, polyoxymethylene cellulose acetate, polystyrene, polytetrafluoroethylene, polyesters, silicone rubber, natural rubber and polycarbonates.
Claim 8
Dependent Claim
41 words
An article for use in association with whole blood, which comprises; a solid polymeric resin substrate; and a compound of the formula: ##STR6## wherein A represents the residue of sodium heparin after removal of the sodium ion, affixed to said substrate.
Claim 9
Dependent Claim
41 words
An article for use in association with whole blood, which comprises; a solid polymeric resin substrate; and a compound of the formula: ##STR6## wherein A represents the residue of sodium heparin after removal of the sodium ion, affixed to said substrate.
Claim 10
Independent Claim
49 words
A method of improving the blood compatibility of a solid polymeric resin which comprises affixing thereto a compound of the formula: ##STR7## wherein R is alkyl of 12 to 18 carbon atoms, inclusive, R 1 is lower alkyl and A represents the negative ion of a salt of heparin.
Claim 11
Independent Claim
49 words
A method of improving the blood compatibility of a solid polymeric resin which comprises affixing thereto a compound of the formula: ##STR7## wherein R is alkyl of 12 to 18 carbon atoms, inclusive, R 1 is lower alkyl and A represents the negative ion of a salt of heparin.
Claim 12
Dependent Claim
26 words
The method of claim 8 wherein the compound is selected from the group consisting of dodecylmethylammonium chloride, tetradecylmethylammonium chloride, hexadecylmethylammonium chloride, octadecylmethylammonium chloride and dodecylhexylammonium chloride.
References Cited (Backward Citations)
US3634123A
Cited
US3617344A
Cited
US3457098A
Cited
US3514438A
Cited
US3616935A
Cited
US3846353A
Cited
US3755218A
Cited
US3810781A
Cited
US3844989A
Cited
US4118485A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-11-23 | 1985-05-25 | 1985-11-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-11-23 | 1989-05-25 | 1989-11-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-11-23 | 1993-05-25 | 1993-11-24 | $7700.00 | Window Closed / Lapsed |